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Objectives: The aim of this study was to describe the current issues surrounding
Coverage with Evidence Development (CED). CED is characterized by restricted
coverage for a new technology in parallel with targeted research when the stated goal of
the research or data collection is to provide definitive evidence for the clinical or
cost-effectiveness impact of the new technology.
Methods: Presented here is information summarized and interpreted from presentations
and discussions at the 2008 Health Technology Assessment International (HTAi) meeting
and additional information from the medical literature. This study describes the differences
between CED and other conditional coverage agreements, provides a brief history of
CED, describes real-world examples of CED, describes the areas of consensus between
the stakeholders, discusses the areas for future negotiation between stakeholders, and
proposes criteria to assist stakeholders in determining when CED could be appropriate.
Results: Payers could interpret the evidence obtained from a CED program either
positively or negatively, and a range of possible changes to the reimbursement status of
the new technology may result. Striking an appropriate balance between the demands for
prompt access to new technology and acknowledging that some degree of uncertainty will
always exist is a critical challenge to the uptake of this innovative form of conditional
coverage.
Conclusions: When used selectively for innovative procedures, pharmaceuticals, or
devices in the appropriate disease areas, CED may provide patients access to promising
medicines or technologies while data to minimize uncertainty are collected.
Keywords: Coverage with Evidence Development, Insurance coverage, Economics,
Evidence-based healthcare
Coverage with Evidence Development (CED) is a form
of conditional reimbursement for pharmaceutical products,
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medical/surgical procedures, and medical devices. CED is
characterized by restricted coverage occurring in parallel
with targeted data collection and when the stated goal of
the research is reducing material uncertainty. Material uncer-
tainty exists when the clinical or cost-effectiveness impact of
a new technology is not robustly characterized, and the effect
of more accurately defining the clinical or cost-effectiveness
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impact may provide definitive information. Payers and other
healthcare decision makers may interpret the additional ev-
idence obtained from a CED program either positively or
negatively, requiring a range of possible changes to the re-
imbursement status.
CED may be appropriate when the benefit profile of
an innovation is uncertain, and data collection required by
CED can be structured to minimize uncertainty around a
specific aspect of the evidence base. CED has a poten-
tial impact on payers (e.g., private insurance companies,
reimbursement agencies, and government bodies) and pro-
ducers (e.g., pharmaceutical companies and device compa-
nies), but CED may also impact patients and healthcare
providers who may want access to new treatments in the
face of uncertainty. The key issue is striking an appro-
priate balance between the demands for prompt access to
promising technologies and acknowledging that some de-
gree of uncertainty about the clinical and cost-effectiveness
of a technology is almost always present around the time of
launch.
A manuscript developed by Hutton et al. describes the
work of the Health Technology Assessment International
(HTAi) Policy Forum in 2007 in consideration of CED (10).
The study concluded that when coverage decisions are made
close to launch, the data required for regulatory approval may
be not be sufficient for coverage decisions/reimbursement.
CED provides an option for collecting evidence to meet the
needs of payers without delaying access to new treatments
for all patients.
In this study, we describe how CED differs from other
conditional coverage agreements, provide a brief history of
CED, describe several real-world examples of CED from dif-
ferent countries, describe the areas of consensus between the
stakeholders, discuss the areas of contention between stake-
holders, and propose criteria to assist payers in determining
when CED could be appropriate.
For this study, stakeholders include patients, producers,
payers, and healthcare providers. Producers are generally
the developers, marketers, or owners of the new technology.
Payers include private and public sector bodies that fund
health services and the decision-making bodies that influence
funding decision on a national or regional level.
The primary sources for this study were the CED presen-
tations that took place at the Health Technology Assessment
International (HTAi) meeting in Montreal, Canada, in July
2008. The information from the presentations was primarily
from the perspective of producers and payers. Most of the
examples of experience with CED presented at the meeting
were those associated with large, government-run, healthcare
delivery systems. The information from the presentations
is supplemented with information from other publications
and Internet sources identified by a search of MED-
LINE (http://www.ncbi.nlm.nih.gov/pubmed/) and Google
Scholar (http://scholar.google.com/) and referenced in this
study.
COVERAGE WITH EVIDENCE
DEVELOPMENT AS A FORM OF
CONDITIONAL COVERAGE
Conditional coverage can be defined as a recommendation
for reimbursement or coverage for a new product with asso-
ciated limitations that may relate to the eligibility of specified
patient groups or to specified dose or duration requirements.
Conditional coverage agreements may be designed to limit
the budget impact of a new innovation and to focus the pro-
motion and utilization of the product to situations where
cost-effectiveness is well defined. Table 1 describes differ-
ent types of conditional coverage agreements including risk-
sharing agreements, dose capping, price-volume agreements,
and outcomes-based reimbursement schemes.
CED is distinct from other forms of conditional cover-
age because the stated goal of CED is to generate evidence to
validate current decisions and inform future decisions. CED
differs from other conditional coverage agreements (e.g., risk
sharing) in that it acknowledges that the coverage decision
is characterized by uncertainty about the effectiveness of a
technology but then goes on to put in place steps to address
the uncertainty. One could argue that the other forms of con-
ditional coverage are more limited in that they use uncertainty
as a mechanism to adjust financial flows (e.g., by discount-
ing prices or providing rebates under certain conditions) but
make no attempt to reduce the uncertainty.
A BRIEF HISTORY OF COVERAGE WITH
EVIDENCE DEVELOPMENT
The term CED was coined by the Center for Medicare and
Medicaid Services (CMS) in the United States (US) when
the organization developed a program to evaluate a specific
surgical procedure for the treatment of emphysema. Other
terms for CED include “Special Arrangement for Clinical
Government Research and Audit” for interventional proce-
dures and “Only in Research” (OIR) for pharmaceuticals
in the United Kingdom (UK), “Conditionally Funded Field
Evaluation” (CFFE) in Canada. Australia and France use the
term CED. France also uses the term “ Still in Research,”
and Spain considers the practice “Monitored Use.”
In 2006, CMS published a revised guidance document
that clarified descriptions of two key elements of CED (2).
The document describes “coverage with appropriateness de-
termination,” which refers to the collection of data to con-
firm that a new technology is being used as described by the
coverage decision documentation, and “coverage with study
participation,” which refers to situations in which the new
technology could be deemed reasonable and necessary if pa-
tients were enrolled in a clinical trial but adequate evidence
for all necessary standards was lacking (17).
In Canada, CFFE is encouraged for products and innova-
tions with a large potential investment, potentially disruptive
effects, and a need for quality control. The application of
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Table 1. Description of Types of Conditional Coverage for New Technologies in Health Care
Type of conditional coverage Description
CED A form of conditional reimbursement and is characterized by restricted coverage
occurring in parallel with targeted data collection and when the stated goal of the
research is reducing material uncertainty. Material uncertainty exists when the clinical
or cost-effectiveness impact of a new technology is not robustly characterized, and the
effect of more accurately defining the clinical or cost-effectiveness impact may
provide definitive information.
Risk-sharing agreement An agreement between a producer and a payer to share the financial risks that may arise
from inappropriate use of a new technology. Examples of inappropriate use include
use outside an agreed and specified patient population or lower than expected
effectiveness of a technology. Depending on how the agreement is structured, a
risk-sharing agreement may be seen as a flexible pricing arrangement. If payers do not
fully accept the value proposition as described by the producer and are unwilling to
pay the producer’s full price for a new technology for all potential patients, a
risk-sharing agreement is a method to limit uptake and help target a new technology to
the most appropriate population
Dose capping A situation where the payer agrees to cover a limited number of doses or a lower dose
per patient than recommended by the producer.
Price-volume agreement An agreement that the payer provides high-needs patients with a product and pays the
price proposed by the producer. If the product becomes widely prescribed, the amount
of money paid by the payer also decreases. The rate of uptake of an innovation may be
slowed. This type of agreement is more likely if potential responders can be easily
identified, and is most suitable in situations where uncertainty is limited to appropriate
adoption rate and/or the population most likely to benefit. This is a more specific form
of risk sharing, but with most risk taken by the producer. A price-volume agreement
may be appropriate for products if the licensed indication includes a large number of
patients, but the effectiveness or cost-effectiveness appears to vary significantly across
the population.
Outcomes-based reimbursement schemes A reimbursement scheme that may be suitable if patients’ response to treatment is
uncertain. In this situation, risk sharing is more closely tied to health outcomes. The
payer may agree to provide a set number of treatments per patient. If the patient meets
predetermined markers for progress, the payer provides additional treatments. If not,
the producer pays rebates for all or part of the therapy (4).
CED, Coverage with Evidence Development.
field evaluations in health technology assessments in On-
tario, Canada, is described in a recent publication (9).
In the United Kingdom, the National Institute for Health
and Clinical Excellence (NICE) does not negotiate the prices
for pharmaceuticals or devices. The prices are set by the pro-
ducer, and NICE conducts assessments and provides guid-
ance for local health authorities. NICE is under remit to
avoid rejection of a product because of estimates of total
expenditure, but budget impact must be considered part of
the evaluation. However, rejection of a product based on
cost-effectiveness is implicitly a rejection on the grounds of
cost. In 2010, NICE is expected to release guidelines with
new suggestions for handling uncertainty including issues
surrounding subgroup analyses, optimal stopping rules for
therapy, real-world analyses, and scheme evaluations. NICE
considers input from patients and the public when develop-
ing recommendations through the Citizens’ Council, and the
Citizens’ Council has provided feedback on the conditions
for applying OIR status (3).
In Australia, the use of CED for pharmaceutical products
has been limited. Difficulties with implementation and the
limited remit of the Pharmaceutical Benefits Advisory Com-
mittee (PBAC), which evaluates submissions received with
limited solutions to access for treatments, have contributed
to slow uptake of CED. The role of the PBAC is to identify
the presence and extent of uncertainty and to decide how that
should impact recommendations for reimbursement.
SELECT EXAMPLES OF CED IN PRACTICE
Surgical Procedures and Medical Devices
In the United States, the CMS was concerned about evidence
of a rapid uptake in lung volume reduction surgery (LVRS)
that appeared to be based on positive results from a small
case series. Coverage of LVRS for Medicare patients was
limited coverage to patients enrolled in the National Em-
physema Treatment Trial (NETT), which began in 1995 and
collected 7 years of data (17). Patients (n = 1,218) were ran-
domized to LVRS or nonsurgical treatment. The study cost
US$60 million. No survival benefits were observed in the
study population or high-risk patient subgroups. The surgery
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was associated with an increase in mortality. Due to deficien-
cies in coding designations, accurate tracking of the number
of procedures was not possible. However, the code that in-
cluded LVRS indicated that approximately 5,000 surgeries
per year were being conducted before the results of the trial
were reported, and that number has decreased to only a few
hundred per year in the years since. This is an example of
CED for a procedure without a designated producer.
In Ontario, Canada, an observational study was con-
ducted to compare drug-eluting stents (DES) and bare metal
stents (BMS) in an observational study using propensity
score matched patients (15). DES were more effective, but
greater benefits were observed in subgroups including pa-
tients with diabetes, and small and large diameter lesions.
The recommendation was that DES should be used in pa-
tients who meet the criteria for one or more of these sub-
groups. While the uptake of DES in the absence of these
data is not possible to calculate, researchers believe that the
CAN$23 million per year spent on DES is less than it would
have been without the program based on uptake rates from
the United States.
In Australia, surgical intervention for abdominal aortic
aneurysm was diffusing rapidly. In the late 1990s, the Medi-
care Services Advisory Committee (MSAC) granted limited
funding under the condition of evidence development. The
Department of Health funded the data collection for 5 years.
Results from randomized controlled trials and reviews of
data from other countries led the MSAC to recommend un-
restricted funding of open aortic repair (11).
Pharmaceuticals
In the United Kingdom, the NHS and four manufacturers
have agreed to a CED program that allows 5,000 patients
access to beta interferon and glatiramer for the treatment of
multiple sclerosis. Access was contingent upon the results
of the data collected in patients enrolled in the program.
The uncertainty here was around the claimed incremental
cost-effectiveness ratio. However, because of the high unmet
medical need and the basic plausibility of the claim, coverage
was provided but contingent on the collection of data to close
the evidence gap. Specifically, the study was designed to
identify the cost-effectiveness ratio for the new treatment and
compare it with the target threshold of £36,000 per quality-
adjusted life-year (8). The expectation is that the prices may
need to be adjusted to meet this target, depending on the
effectiveness results of the ongoing studies. The study was
scheduled to be completed in Fall of 2007; however, currently
only limited results and guidance are available (13).
A related example in the United Kingdom is an agree-
ment where manufacturers and payers agreed that bortezomib
(Velcade R©, Millennium) could be reimbursed for multiple
myeloma if data were collected and reported to NICE. The
results will inform a NICE recommendation in 2011 (3).
However, this program is operating as an outcomes-based
risk share, rather than true CED, as the effective price of
the product is modulated by the individual patient outcomes
being experienced, and the data are not designed to fill an
evidence gap.
In Australia, the most comprehensive example of CED
as part of a risk-sharing program is that of bosentan
monohydrate (Tracleer R©) for the treatment of pulmonary
artery hypertension (PAH). A study measuring survival out-
comes to inform drug-pricing decisions is under way as
part of a risk-sharing agreement between the Pharmaceu-
tical Benefits Scheme (PBS) and Actelion Pharmaceuti-
cals. Bosentan is a dual endothelin receptor agonist that
has been approved by the Australia’s Therapeutic Goods
Administration (TGA) and the PBS for the treatment of
primary pulmonary hypertension and PAH associated with
scleroderma, and PAH associated with a congenital systemic-
to-pulmonary shunt (12;14). A recent cost-effectiveness anal-
ysis estimated that bosentan costs $A39,300 per patient per
year using 2004 PBS costing (19). The Bosentan Patient Reg-
ister, funded by Actelion, evaluates the survival outcomes of
bosenan-treated patients over a 3-year period (1). Enrollment
is optional for patients and independent of access to bosentan.
Patients who disenroll may retain access to bosentan. How-
ever, all bosentan-treated patients receive treatment based on
their response to the drug over the previous 6-month period.
Nonresponders are denied access to treatment regardless of
their registry enrollment status, but nonresponders remain
enrolled in the registry. The PBS intends to use the survival
data to evaluate the cost-effectiveness results predicted by
economic modeling and will use the information to adjust
the price of bosentan with the goal of maintaining the incre-
mental cost-effectiveness ratio predicted by the model (19).
AREAS OF CONSENSUS AND
CONTENTION SURROUNDING CED
Based on the presentations at the HTAi meeting, the authors
identified six areas of agreement between payers and produc-
ers (Table 2), and six areas that the authors believe require fur-
ther consideration and discussion by stakeholders (Table 3).
The authors do not consider these issues to be barriers to the
uptake of CED, but rather issues to consider when developing
programs and studies.
When considering the issues for future consideration,
the first two issues listed in Table 3 are potentially the most
pressing issues to be addressed by stakeholders. The first
area for consideration focuses on the responsibility for fund-
ing the additional research required for CED—the payer or
the producer. While evidence suggests that public sector cov-
erage of research costs could be offset by price discounts or
other pricing agreements (6), payers are concerned that pub-
lically funded, evidence development could inadvertently
incentivize producers to provide incomplete submission
packages. Other experts believe that payer-funded research
is necessary to provide control over research design and data
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Table 2. Areas of Consensus Among CED Stakeholders
CED should be the exception and not the
rule
All stakeholders agree that decisions must be made in the face of some uncertainty. CED
should only be applied when the uncertainty is material, and the additional evidence
required is obtainable.
CED requires well-developed and
well-designed studies
Appropriate study design is required to capture meaningful data to answer the
outstanding questions that created the need for CED. The evidence must be
appropriate and of a necessary standard for its intended use
The timing of key results is critically
important
The timing of results reporting should be evaluated on a case-by-case basis and should
include consideration of future treatments. If the treatment is likely to become
obsolete before the results can be collected and reported, stakeholders would not view
the program favorably. However, stakeholders agree that studies should not be rushed
at the expense of comprehensive and meaningful results
Choosing appropriate therapies is critical
for success of CED
Currently the level of experience with CED is limited and additional experience in the
development and implementation of CED programs is necessary to define the specific
criteria that should be used to identify appropriate technologies for CED programs
The evidence gap must be defined prior
to the collection of new evidence
Producers and payers must be in agreement on the decision points and the quality of the
evidence to be obtained before the program is implemented.
CED should not be used to delay access
to new technology
When a new technology has the potential to deliver health benefits to patients, CED
should not be used solely to slow uptake of the new product.
CED, Coverage with Evidence Development.
Table 3. Areas Requiring Future Consideration by CED Stakeholders
Responsibility for funding The responsibility for funding of the additional research has not been clearly defined.
Producers, payers (including private and publically funded payers), or both may be
required to fund additional research for CED
Disincentives the development of new
technologies
Producers may believe they are assuming the majority of the risk when initiating a CED
program.
CED could stifle innovation by creating a disincentive to develop new products for
conditions for which the evidence base is not well developed.
A disincentive related to research design and funding is that restricted access to new
products could inadvertently delay the collection and communication of new data
because the treatment population would remain limited in size.
Issues with reversing a decision Payers may believe that withdrawing coverage, even conditional coverage, is logistically
and politically difficult even if the product does not meet the predetermined criteria for
effectiveness or cost-effectiveness. Payers are less concerned about reversing a “no”
decision than they are about reversing a “conditional yes” decision. Payers may have a
limited view of the options available to them if the evidence is not supportive.
Producers and health technology researchers are likely to encourage payers to think
creatively about listing decisions and consider forms of conditional or restricted
coverage or price sharing with patients or producers. One suggestion is that coverage
should not be considered a dichotomous outcome, reimburse or de-list, because other
options may be negotiated.
Consensus on standards for study design The preferred study design required to answer questions of evidence development has
not been clearly defined. Some stakeholders suggest that only randomized, controlled
prospective studies can provide evidence of sufficient quality for CED, but other see a
place for observational studies and studies of non-experimental design. Randomized,
controlled studies will be more expensive to conduct, and will provide fewer patients
with access to the new treatment.
Unfairness in the allocation of new
treatment
Some stakeholders argue that it may be unethical to withhold a potentially beneficial
innovation from a subset of patients while providing it to another. If a potentially
beneficial treatment is withheld from half of the eligible population as part of
randomization, patient advocacy groups may be unwilling to accept this option,
especially if the treatment has demonstrated safety and efficacy.
The need for country-specific evidence The need to provide evidence that can be shared across countries is open to debate.
Providing payers with locally relevant data may not be necessary. Collecting and
disseminating local data can significantly add to the cost of CED programs, and while
providers and payers may be more accepting of local data, the evidence gaps are
unlikely to be dependent on local circumstances, and could be addressed using studies
from other countries.
CED, Coverage with Evidence Development.
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collection (16). For technologies without producers, insurers
could share the costs of research based on a percentage of
collected premiums (18).
Second, the incentive for producers to agree to a CED
program is open for debate. The speculation is that producers
and HTA agencies may disagree on the adequacy of avail-
able data or whether a CED approach is justified. Producers
may agree to CED for products that would otherwise receive
a negative coverage decision based on the data available at
launch. Producers may also be concerned that the likelihood
of a price decrease in a scenario where the technology does
not perform as well as predicted is more likely than a price
increase in situations where the performance of the new tech-
nology is better than expected.
Producers are concerned that CED could negatively im-
pact their return on investment by slowing the uptake of their
product thus delaying peak sales until near the end of their
period of exclusivity. In some cases, this may unintentionally
provide an incentive for “fast followers” in a new drug class
or for new type of technology by placing a greater evidence
burden on the first product to market. This concern illustrates
the need to regard evidence development as fit for purpose
and plan accordingly
Suggested Criteria for CED
While stakeholders appear to be in agreement that CED is
not appropriate for all types of interventions, the criteria for
determining the situation for which CED should be applied
remains unclear. Some stakeholders believe that CED should
only be used in situations where material uncertainty exists,
but what may be deemed as “material” to a payer may not
seem so to the producer and vice versa. A second suggestion
is that CED is more likely to be applied when treatments may
be highly effective for a subset of patients and less likely to
be effective for a large group of patients. Studies designed
to measure the safety and efficacy of a new technology may
not be appropriately designed or powered to determine effi-
cacy or safety in a subpopulation. Payers may be interested
in restricting coverage to a subpopulation and a CED pro-
gram may be appropriate for defining the characteristics of
the target subpopulation. A third observation is that CED
could provide a new coverage option for technologies with
incomplete evidence and the potential to diffuse quickly. A
final observation is that CED is more likely to be applied in
conditions with high unmet need.
This study proposes the following six criteria to evaluate
new technologies to ascertain if CED could be appropriate:
(i) High unmet clinical need or significant improvement in
outcomes is still required. (ii) The value proposition for the
product in question is logical and theoretically valid, but one
or more pieces of evidence are still lacking. In some cases, the
evidence that is lacking may relate to the impact of the treat-
ment on long-term outcomes, and stakeholders may need to
identify one or more suitable interim markers of effectiveness
that will help resolve the uncertainty. (iii) Data collection is
the best solution to resolve the uncertainty (and can be done
in a “fit for purpose” manner, such as a RCT, observational
study, registry, or other well-designed study). (iv) More tradi-
tional coverage tools are not appropriate (e.g., price-volume
agreements) to resolve the clinical or cost-effectiveness un-
certainty. (v) The primary concern is uncertainty surrounding
clinical or cost-effectiveness outcomes and not purely finan-
cial/budget impact. (vi) Stakeholders agree that the evidence
development can be achieved in a timely manner to ensure
that the context of the findings is still relevant within the
current operating environment.
When used selectively for innovative procedures, phar-
maceuticals, or devices in the appropriate disease areas, CED
may help provide access to promising medicines or tech-
nologies while data that will minimize the uncertainty that
surrounds key issues are collected. However, steps should be
taken to ensure that the benefits of additional evidence are
greater than the cost of a delayed decision. Claxton and others
have described approaches to Value of Information analysis
(5;7). Whereas this is an important perspective, there will
be circumstances where the most pragmatic approach is to
undertake CED. Whether or not the Value of Information
justifies the conduct of the CED will relate to the unmet clin-
ical need, the type of data required, and the ease of agreeing
the action to be taken when the further evidence is available
(whether that is supportive or not).
CED has been used successfully in several countries, al-
beit mainly for devices and nonpharmaceutical interventions.
This study illustrates the areas of consensus and the areas of
outstanding issues to assist stakeholders in determining the
appropriateness of the applicability of CED for a particular
innovation. Further experience, especially with pharmaceu-
ticals, will demonstrate the benefits and shortfalls of CED.
As more examples of CED become available, the authors
are confident that consensus around many of the elements is
likely to develop.
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